Bespak has signed an MOU with SNBL to provide immediate and exclusive global access to SNBL’s proprietary nasal dry powder delivery device for developers of novel intranasal therapies.

The agreement strengthens Bespak’s nasal drug delivery offering, which now spans liquid, soft mist and dry powder products from early development through to commercial supply.

The device will be marketed as the Air Pump Unit Dose Intranasal Powder device. It is single-use, compact and easy to carry, delivering powder intranasally from a drug-containing nozzle attached to a simple user-activated air pump. It does not require patients to coordinate breathing during administration.

Nasal drug delivery is attracting growing interest for CNS and systemic routes, with potential applications in pain, neurological conditions, degenerative diseases and vaccines.

SNBL’s device, approved as part of Satsuma Pharmaceuticals’ Atzumi migraine treatment in April 2025, is one of only three FDA-approved dry powder nasal devices available. Bespak is the chosen contract manufacturer for filling and assembly of Atzumi, offering customers a faster and lower-risk route to approval in the US and other regulated markets.

Chris Hirst, CEO of Bespak, said: “Nasal drug delivery is entering an exciting new era, with developers looking for solutions that can deliver next-generation therapies effectively while also meeting patients’ needs for greater convenience and ease of use.

“Our agreement with SNBL strengthens Bespak’s ability to respond to that need, bringing together an FDA-approved dry powder nasal device with our capabilities in formulation, development and commercial manufacturing. Our ambition is to help our customers unlock the potential of nasal delivery and bring more nasal drug breakthroughs to patients.”

Northwest Biotherapeutics and NHS Blood and Transplant have agreed a collaboration to support production of DCVax-L, a personalised immunotherapy for solid tumour cancers. The partnership will begin in Leeds and Oxford, with plans to extend services across England.

DCVax-L uses a patient’s own immune system to recognise and attack cancer. Each treatment is manufactured individually using immune cells collected from the patient and material from the tumour.

Under the agreement, NHS Blood and Transplant will provide specialist services to collect and process patients’ immune cells for DCVax-L manufacturing. This includes leukapheresis, an established procedure that collects specific white blood cells while returning remaining blood components to the body, alongside specialist cell processing and handling delivered by Cellular and Molecular Therapies teams.

Working with Northwest Biotherapeutics and Advent Bioservices, NHS Blood and Transplant will help strengthen UK infrastructure supporting DCVax-L production.

The organisations are also exploring opportunities to expand the collaboration across NHS Blood and Transplant’s network of specialist facilities. This could reduce the distances patients and families need to travel.

Linda Powers, CEO of Northwest Biotherapeutics, said: “NHSBT’s impressive expertise and facilities for advanced therapies are at the forefront of the field.

“We are very excited about collaborating with them on our DCVax-L personalised immune therapies for cancer. We believe NHSBT’s capabilities can significantly enhance the scale-up and accessibility of DCVax-L.”